NCT05282901View on ClinicalTrials.gov

Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

May 30, 2025

Study Completion Date

November 15, 2026

Conditions

Metastatic Uveal Melanoma

Interventions

DRUG

Pembrolizumab 25 MG/1 ML Intravenous Solution

Taken together, we hypothesize that combining pembrolizumab with lenvatinib in metastatic UM may target essential cellular oncogenic pathways while normalizing tumor vascularization, thus allowing an increased infiltration of the tumor by immune cells and an improved immune response.

Trial Locations (1)

75005

Institut Curie, Paris

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Institut Curie

OTHER